



**NEWS RELEASE**

**FOR IMMEDIATE RELEASE**

**SeptRx® begins CE Mark trial of the  
SeptRx® Intrapocket PFO Occluder (IPO)**

**InterSEPT™ trial underway at Sankt Katharinen Hospital, Frankfurt,  
under principal investigator Horst E. Sievert, M.D.**

**The SeptRx® IPO is designed to close “hole in the heart” defects and  
lower the risk of stroke, the second-leading cause of death worldwide**

FREMONT, Calif., June 16, 2011—**SeptRx**, an emerging medical device company that is developing the **SeptRx® Intrapocket PFO Occluder (IPO)**—a platform for the percutaneous transcatheter closure of a heart defect known as *patent foramen ovale* (PFO)—announced today that the first implants have been completed in the **InterSEPT™** clinical trial at the CardioVascular Center at Sankt Katharinen Hospital, Frankfurt, under principal investigator Horst E. Sievert, M.D.

InterSEPT™ (In-tunnel SeptRx European PFO Trial) is a prospective, multi-center, single-arm safety and efficacy trial of the SeptRx® IPO. Data from InterSEPT™ will be used to apply for CE marking. **The SeptRx® Intrapocket PFO Occluder has already completed a successful 11-patient first-in-human (FIH) clinical trial. SeptRx’s FIH trial was the first and only PFO device trial to demonstrate 100% closure and 100% safety (out to 3 years).**

“Stroke is an international health issue, the second most common cause of death and the most common cause of disability worldwide,” said **Scott Russell**, CEO. “Unfortunately, some 20% of all strokes can be attributed to PFO. SeptRx believes that we can have a dramatic influence on lowering this deadly risk. Indeed, we expect that our InterSEPT™ trial results will position us for initial commercialization efforts in Europe.”

*PFO* is a tunnel-like defect connecting the right atrium with the left atrium. A remnant of fetal circulation, it usually seals itself within a few months after birth. Unfortunately, in about 25% of the population the *PFO* does not fully close and may allow blood (and emboli) to pass directly between the right and left atria. The presence of a *PFO* has been identified as a contributing factor in cryptogenic stroke, chronic migraine, decompression sickness, and obstructive sleep apnea. A *PFO* contributes to these conditions by providing a pathway for emboli (blood clots, air bubbles) in the venous system to reach the arterial system by passing directly from the right atrium to the left.

SeptRx, Inc. is an emerging medical device company that is developing the SeptRx® Intrapocket PFO Occluder (IPO), a platform for the percutaneous transcatheter closure of a heart defect known as *patent foramen ovale* (PFO).

NOTICE: The SeptRx® IPO is not approved for sale in any regulatory jurisdiction. Further, it is not yet available for investigational use or commercial sale in the U.S.

#####